The individual's healthcare in the last 12 months of life costs about 25% of total healthcare costs for that person's life. Should policy makers’ better control end-of-life costs? This is just one of many questions addressed in this segment about weighing the effectiveness of treatment vs. cost. Join us as host Dr. Bill Rutenberg interviews Senior Medical Economist of the Rand Corporation, Geoffrey Joyce PhD.
Health Policy: Weighing Treatment Effectiveness vs. Cost

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The individual's healthcare in the last 12 months of life costs about 25% of total healthcare costs for that person's life. Should policy makers’ better control end-of-life costs? This is just one of many questions addressed in this segment about weighing the effectiveness of treatment vs. cost. Join us as host Dr. Bill Rutenberg interviews Senior Medical Economist of the Rand Corporation, Geoffrey Joyce PhD.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?